Skip to main content

Table 2 Tumor response rate and survival according to therapy line

From: Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma

Efficacy endpoints 1st line (n = 12) 2nd line (n = 20) Overall (n = 32)
  No. (%) No. (%) No. (%)
Complete response 2 (16.7) 1 (5.0) 3 (9.4)
Partial response 7 (58.3) 8 (40.0) 15 (46.9)
Stable disease 0 (0.0) 6 (30.0) 6 (18.7)
Progressive disease 3 (25.0) 5 (25.0) 8 (25.0)
Overall response rate 9 (75.0) 9 (45.0) 18 (56.3)*
  1. *(95%Confidence Interval; 39.0-73.4)